These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22926062)

  • 21. Promotion of tumor progression induced by continuous low-dose administration of antineoplastic agent gemcitabine or gemcitabine combined with cisplatin.
    Chen Y; Liu H; Zheng Q; Li H; You H; Feng Y; Feng W
    Life Sci; 2022 Oct; 306():120826. PubMed ID: 35870618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
    Maletzki C; Wiegele L; Nassar I; Stenzel J; Junghanss C
    J Immunother Cancer; 2019 Jan; 7(1):8. PubMed ID: 30630527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
    Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
    Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
    Ko HJ; Kim YJ; Kim YS; Chang WS; Ko SY; Chang SY; Sakaguchi S; Kang CY
    Cancer Res; 2007 Aug; 67(15):7477-86. PubMed ID: 17671218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
    Correale P; Rotundo MS; Del Vecchio MT; Remondo C; Migali C; Ginanneschi C; Tsang KY; Licchetta A; Mannucci S; Loiacono L; Tassone P; Francini G; Tagliaferri P
    J Immunother; 2010 May; 33(4):435-41. PubMed ID: 20386463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
    Mundy-Bosse BL; Lesinski GB; Jaime-Ramirez AC; Benninger K; Khan M; Kuppusamy P; Guenterberg K; Kondadasula SV; Chaudhury AR; La Perle KM; Kreiner M; Young G; Guttridge DC; Carson WE
    Cancer Res; 2011 Aug; 71(15):5101-10. PubMed ID: 21680779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Supplementation of l-arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy.
    Satoh Y; Kotani H; Iida Y; Taniura T; Notsu Y; Harada M
    Cancer Sci; 2020 Jul; 111(7):2248-2258. PubMed ID: 32426941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer.
    Tomihara K; Fuse H; Heshiki W; Takei R; Zhang B; Arai N; Nakamori K; Noguchi M
    Oral Oncol; 2014 May; 50(5):457-67. PubMed ID: 24582211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
    Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
    Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue- and Temporal-Dependent Dynamics of Myeloablation in Response to Gemcitabine Chemotherapy.
    Kitelinger LE; Thim EA; Zipkowitz SY; Price RJ; Bullock TNJ
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells.
    Liu Y; Yu Y; Yang S; Zeng B; Zhang Z; Jiao G; Zhang Y; Cai L; Yang R
    Cancer Immunol Immunother; 2009 May; 58(5):687-97. PubMed ID: 18828017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
    Banissi C; Ghiringhelli F; Chen L; Carpentier AF
    Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
    Qu X; Felder MA; Perez Horta Z; Sondel PM; Rakhmilevich AL
    Int Immunopharmacol; 2013 Dec; 17(4):1141-7. PubMed ID: 24201083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine.
    Mortara L; Orecchia P; Castellani P; Borsi L; Carnemolla B; Balza E
    Cancer Med; 2013 Aug; 2(4):478-87. PubMed ID: 24156020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
    Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
    J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
    Doloff JC; Chen CS; Waxman DJ
    Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth.
    Parra K; Valenzuela P; Lerma N; Gallegos A; Reza LC; Rodriguez G; Emmenegger U; Di Desidero T; Bocci G; Felder MS; Manciu M; Kirken RA; Francia G
    Br J Cancer; 2017 Jan; 116(3):324-334. PubMed ID: 28056464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy.
    van der Most RG; Currie AJ; Mahendran S; Prosser A; Darabi A; Robinson BW; Nowak AK; Lake RA
    Cancer Immunol Immunother; 2009 Aug; 58(8):1219-28. PubMed ID: 19052741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.